Steven Fishbane1, Mohamed A El-Shahawy2, Roberto Pecoits-Filho3,4, Bui Pham Van5, Mark T Houser6, Lars Frison7, Dustin J Little6, Nicolas J Guzman6, Pablo E Pergola8. 1. Department of Medicine, Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, New York sfishbane@northwell.edu. 2. Department of Medicine, Keck-University of Southern California School of Medicine, Los Angeles, California. 3. School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil. 4. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 5. Department of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. 6. Global Medicines Development, Biopharmaceuticals Research & Development, AstraZeneca Gaithersburg, Gaithersburg, Maryland. 7. Biostatistics, Biopharmaceuticals Research & Development, AstraZeneca Gothenburg, Mölndal, Sweden. 8. Renal Associates PA, San Antonio, Texas.
Abstract
BACKGROUND: Current anemia therapies for patients with non-dialysis-dependent CKD may require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis and improves iron homeostasis. METHODS: In this double-blind phase 3 study, we randomized patients with non-dialysis-dependent CKD stages 3-5 and hemoglobin <10.0 g/dl (1:1) to thrice-weekly 70-mg oral roxadustat or placebo. Doses were titrated throughout the study based on hemoglobin levels. The primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28-52 versus placebo, irrespective of rescue therapy use. We assessed patients for adverse events. RESULTS: The study included 2781 patients, 1393 who received roxadustat and 1388 who received placebo. Mean baseline hemoglobin was 9.1 g/dl for both groups. The mean change in hemoglobin from baseline was 1.75 g/dl (95% confidence interval [95% CI], 1.68 to 1.81) with roxadustat versus 0.40 g/dl (95% CI, 0.33 to 0.47) with placebo, (P<0.001). Among 411 patients with baseline elevated high-sensitivity C-reactive protein, mean change in hemoglobin from baseline was 1.75 g/dl (95% CI, 1.58 to 1.92) with roxadustat versus 0.62 g/dl (95% CI, 0.44 to 0.80) with placebo, (P<0.001). Roxadustat reduced the risk of red blood cell transfusion by 63% (hazard ratio, 0.37; 95% CI, 0.30 to 0.44). The most common adverse events with roxadustat and placebo, respectively, were ESKD (21.0% versus 20.5%), urinary tract infection (12.8% versus 8.0%), pneumonia (11.9% versus 9.4%), and hypertension (11.5% versus 9.1%). CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with non-dialysis-dependent CKD and reduced the need for red blood cell transfusion, with an adverse event profile comparable to that of placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With CKD, Not on Dialysis, NCT02174627.
BACKGROUND: Current anemia therapies for patients with non-dialysis-dependent CKD may require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis and improves iron homeostasis. METHODS: In this double-blind phase 3 study, we randomized patients with non-dialysis-dependent CKD stages 3-5 and hemoglobin <10.0 g/dl (1:1) to thrice-weekly 70-mg oral roxadustat or placebo. Doses were titrated throughout the study based on hemoglobin levels. The primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28-52 versus placebo, irrespective of rescue therapy use. We assessed patients for adverse events. RESULTS: The study included 2781 patients, 1393 who received roxadustat and 1388 who received placebo. Mean baseline hemoglobin was 9.1 g/dl for both groups. The mean change in hemoglobin from baseline was 1.75 g/dl (95% confidence interval [95% CI], 1.68 to 1.81) with roxadustat versus 0.40 g/dl (95% CI, 0.33 to 0.47) with placebo, (P<0.001). Among 411 patients with baseline elevated high-sensitivity C-reactive protein, mean change in hemoglobin from baseline was 1.75 g/dl (95% CI, 1.58 to 1.92) with roxadustat versus 0.62 g/dl (95% CI, 0.44 to 0.80) with placebo, (P<0.001). Roxadustat reduced the risk of red blood cell transfusion by 63% (hazard ratio, 0.37; 95% CI, 0.30 to 0.44). The most common adverse events with roxadustat and placebo, respectively, were ESKD (21.0% versus 20.5%), urinary tract infection (12.8% versus 8.0%), pneumonia (11.9% versus 9.4%), and hypertension (11.5% versus 9.1%). CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with non-dialysis-dependent CKD and reduced the need for red blood cell transfusion, with an adverse event profile comparable to that of placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With CKD, Not on Dialysis, NCT02174627.
Authors: Junichi Hoshino; Daniel Muenz; Jarcy Zee; Nidhi Sukul; Elodie Speyer; Murilo Guedes; Antonio A Lopes; Koichi Asahi; Heleen van Haalen; Glen James; Nafeesa Dhalwani; Roberto Pecoits-Filho; Brian Bieber; Bruce M Robinson; Ronald L Pisoni Journal: J Ren Nutr Date: 2020-01-21 Impact factor: 3.655
Authors: M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: Jeffrey L Carson; Brenda J Grossman; Steven Kleinman; Alan T Tinmouth; Marisa B Marques; Mark K Fung; John B Holcomb; Orieji Illoh; Lewis J Kaplan; Louis M Katz; Sunil V Rao; John D Roback; Aryeh Shander; Aaron A R Tobian; Robert Weinstein; Lisa Grace Swinton McLaughlin; Benjamin Djulbegovic Journal: Ann Intern Med Date: 2012-07-03 Impact factor: 25.391
Authors: Austin G Stack; Ahmed Alghali; Xia Li; John P Ferguson; Liam F Casserly; Cornelius J Cronin; Donal N Reddan; Wael Hussein; Mohamed E Elsayed Journal: Clin Kidney J Date: 2017-07-13
Authors: Patrizia Natale; Suetonia C Palmer; Allison Jaure; Elisabeth M Hodson; Marinella Ruospo; Tess E Cooper; Deirdre Hahn; Valeria M Saglimbene; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-08-25
Authors: Robert Provenzano; Lynda Szczech; Robert Leong; Khalil G Saikali; Ming Zhong; Tyson T Lee; Dustin J Little; Mark T Houser; Lars Frison; John Houghton; Thomas B Neff Journal: Clin J Am Soc Nephrol Date: 2021-08 Impact factor: 10.614